Treatment of hepatosplenic candidiasis with liposomal-amphotericin B.
Nine patients with hematologic malignancies developed fungal infections, predominantly involving the liver and spleen. Eight patients had biopsy-documented progressive candidiasis and one had an unclassified fungus. The patients were treated with liposomal-amphotericin B (L-AmpB) after their fungal infection progressed during treatment with standard intravenous (IV) AmpB (Fungizone; E. R. Squibb & Son, Princeton, NJ) and/or other antifungals. Eight patients (88.8%) were cured of their fungal infection, and one showed improvement after treatment. Minor acute toxicity and no chronic toxicity were associated with the administration of L-AmpB. L-AmpB is a safe and effective therapeutic method for treating fungal infections that have invaded the liver and spleen even when they are refractory to conventional anti-fungal therapy.
D000293:Adolescent; D000328:Adult; D000666:Amphotericin B / Q000627:therapeutic use*; D002177:Candidiasis / Q000150:complications / Q000188:drug therapy*; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007938:Leukemia / Q000150:complications; D008081:Liposomes / Q000008:administration & dosage; D008107:Liver Diseases / Q000150:complications / Q000188:drug therapy*; D008223:Lymphoma / Q000150:complications; D008297:Male; D008875:Middle Aged; D013158:Splenic Diseases / Q000150:complications / Q000188:drug therapy*
D008081:Liposomes; D000666:Amphotericin B